Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents

Retrovirology

Table 2 RNA measurements of latency reversal after presentation of the indicated antigens by dendritic cells for one of the participants shown in Fig. 4; cells were cultured with or without raltegravir

Assay	DMSO	α-CD3 + α-CD28	CMV pp65	HIV-1 p55 Gag	SIV p55 Gag	CMV pp65 peptide pool^a	CEFT^b peptide pool	HIV-1 Gag peptide pool
cf^c-RNA raltegravir^d	n.d.^e (0)	24,000 (100)	n.d. (0)	130 (0.5)	n.d. (0)	107 (0.4)	n.d. (0)	8300 (35)
cf-RNA no raltegravir^f	n.d. (0)	1.2 × 10¹⁰ (100)	n.d. (0)	1 × 10¹⁰ (87)	370 (3 × 10^− 6)	440 (4 × 10^− 6)	n.d. (0)	33,000 (2.7 × 10^− 4)
ca^g-RNA raltegravir^d	n.d. (0)	151 (100)	3 (2)	n.d. (0)	n.d. (0)	14 (9)	30 (20)	96 (64)
ca^g-RNA no raltegravir^f	n.d. (0)	1.2 × 10⁹ (100)	n.d. (0)	7.5 × 10⁶ (0.63)	n.d. (0)	n.d. (0)	n.d. (0)	50 (4 × 10^− 6)

Values in parentheses are the percent of the α-CD3/α-CD28 control
^aAll peptide pools were used at 1 µg/ml each peptide
^bCEFT, pool of MHC class-II restricted peptides from CMV, EBV, influenza virus, and tetanus toxoid
^ccf, cell-free, virion-associated RNA in copies/ml
^dRaltegravir was used at 1 µM to block viral propagation and the cells were stimulated for 7 days
^en.d., not detected
^fCells were stimulated for 18 days in the absence of raltegravir
^gca, cell-associated, Tat/Rev mRNA in copies/µg RNA

ISSN: 1742-4690